what to do while taking semaglutide π₯ Eat and What to Avoid When for Weight Loss: A Guide π― Maximize your GLP-1 results
Description
After a 36-week lead-in, participants had lost 20.9% of body weight
President Trump recently announced a deal with drugmakers to expand access to GLP-1 drugs to Medicare patients starting in 2026
Healthcare company Ro just launched a GLP-1 supply tracker
It has been an exciting summer for our new GLP-1 weight loss medications, Wegovy (semaglutide) and Zepbound (tirzepatide)
Methods PAM amidation activity, postprandial GLP-1 levels, and the incretin effect were measured in carriers of PAM T2D-risk alleles and matched non-carriers from the Oxford Biobank in a prospective observational study and in Danish cohorts
